Phosphoglycerate kinase (PGK) deficiency is generally associated with chronic hemolytic anemia, although it can be accompanied by either mental retardation or muscular disease. Genomic DNAs of two PGK-deficient patients previously described in France were sequenced directly after polymerase chain reaction amplification. The PGK Creteil variant arises from a G -t A nucleotide interchange at position 1022 in cDNA (exon 9). resulting in amino acid substitution 314 Asp --t Asn in the C-terminal domain, which contains the nucleotide binding site. lt is associeted with rhabdomyolysis crises but not with hemolysis or mental retardation. In HOSPHOGLYCERATE KINASE (adenosine triphosphate [ATP] 3-phosphoglycerate l-phosphotransferase, EC 2.7.2.3: PGK) is a glycolytic enzyme catalyzing the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate that plays a key role in ATP generation during glycolysis. Erythrocyte PGK is a monomeric enzyme that is expressed in all tissues. It is encoded by a single structural gene located on chromosome X in humans,' although a second gene (PG=), which is expressed only in testicular tissue,2 is located on chromosome 19, whereas several pseudogenes are present on chromosomes X and 6.3,4
The complete amino acid and genomic sequences of human PGK are known!. ' The tertiary structure of PGK has been extensively studied in the past at the protein level, using horse-muscle enzyme as a Although the same study was not performed on the human enzyme, their amino acid sequences are closely related8 and therefore the data may be readily extrapolated. Crystallographic studies and x-ray analysis of horse and yeast PGKs have been reported.'.'' Two globular domains contribute to the enzymatic mechanism; they are separated by two stretches of amino acids, one of which is an a helix and the other a random coil.' The N-terminal domain contains the catalytic site for phosphoglycerate binding and the C-terminal domain that for nucleotide binding (ATP or adenosine diphosphate [ADP])."
Deficiency of PGK was first described in 1968,12.13 and until now several cases have been reported. Such a deficiency the other case, which is associated with chronic hemolytic anemia and mental retardation (PGK Amiens), an A -+ T nucleotide interchange was found at position 571 in cDNA (exon 5); this leads to amino acid substitution 163 Asp -+ Val in the N-terminal domain, which contains the catalytic site for phosphoglycerate binding. These results corroborate the kinetic data observed. In the two cases, the mutations are distinct from others previously reported and no significant relationship could be observed between the location of the amino acid substitution and its clinical consequences. 0 1994 by The American Society of Hematology.
is generally associated with hemolysis and neurologic disorders, the latter being variable, often including mental retardation, seizure, emotional lability, and extrapyramidal tract disease.I4 A few variants give rise to muscular symptoms that may be associated with chronic hemolysis. As the PGK gene is linked to the X-chromosome, deficiency is expressed at the clinical level only in males, whereas females, in general, have a normal phenotype, or minor disorders correlated with low PGK activity. The enzyme deficiency could be detected in red blood cells (RBCs), leukocytes, or in any other tissue by enzymatic assay, as a result of the ubiquitous expression of PGK.I4 At the present time, the structure of seven mutants have been described: PGK Shizuoka (157 Gly + Val),'' PGK Munchen (267 Asp + Asn),16 PGK Uppsala (205 Arg + Pro),17 PGK I1 (351 Thr "* Asn)," PGK Michigan (315 Cys + Arg)," PGK Matsue (88 Leu -+ Pro)," and PGK Tokyo (265 Val "* Met)" (all residues reported are referred as the methionine initiator being residue -1). DiMauro's group described two other PGK variants that are associated with muscular disorders, named PGK New Jerseyz2 and PGK Albertaz7 on the basis of enzymatic study and phenotype, but they remain to be studied at the gene level.
This report deals with the reinvestigation at the gene level of two cases of PGK deficiency previously described by their phenotype in France, ie, PGK Amiensz4 and PGK Crkteil?' and the assignment of the abnormality involved in enzyme deficiency. These studies have allowed us to draw conclusions concerning structure-function relationships in the enzyme and to relate them with the clinical disorders.
MATERIALS AND METHODS

Enzymatic Analysis
methods.26
DNA Samples
Erythrocyte PGK activity was determined by previously reported Approximately 5 mL of peripheral blood was withdrawn on EDTA from members of families B and V. DNA was prepared using standard techniques."
In Vitro Amplification
Amplification was performed as previously de~cribed.'~ The oligonucleotides used were designed according to the position of introns and exons to give polymerase chain reaction (PCR) products around 500 to 800 bp. Exons 3 and 4; 5 and 6; 7 and 8; 9 and 10 were amplified during the same reaction together with introns 3, 5, 7, and 9, respectively. Oligonucleotides used in the study are summarized in Table 1 and the position on the PGK gene is indicated in Fig  1 . All oligonucleotides were synthesized by the phosphoramidite chemistry in the laboratory using an Applied Biosystem Instrument apparatus (model 390; Foster City, CA).
Sequence Determination
PCR products were reamplified using a ratio of 0.1: 1 or 0 5 1 of the same oligonucleotides to give rise to single-stranded DNA: ' which was further sequenced using the Sequenase kit (US Biochemicals, Cleveland, OH).** All sequences were made in duplicate on both DNA strand, ie, producing single-stranded DNA with two different asymmetric PCR amplifications on both sides. Alignments of human and animal amino acid sequences PGKs (from version 39 of NBRF-PIR data base) were performed by computer analysis.
RESULTS
Case Reports
Family B. As previously reported:' the proband was a 31-year-old man who was generally in good health with 
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normal intellectual development. He never showed any sign of chronic hemolysis, but since his childhood presented several symptoms during physical exercises, notably rhabdomyolysis crises. Biologic studies showed a decreased PGK activity in erythrocytes, leukocytes, platelets, and on muscular biopsy. The family study showed a low PGK activity in the RBCs of the mother and two daughters of the proband, whereas the PGK activity in his father was normal. These data confirmed the X-chromosome-linked genetic inheritance of the disease. In addition, physical and kinetics studies of the proband's erythrocyte PGK showed a slow-moving electrophoretic band, thermal instability, and increased Km values for ATP and ADP; by contrast Km values for phosphoglycerates were similar to control values. Family V. This case was first reported in 1974 when the proband was 3 years old.24 At this time, the patient manifested chronic hemolytic anemia that was occasionally exacerbated by acute hemolysis crises and associated with retardation in language development. Biologic analyses showed a decreased PGK activity in RBCs and in leukocytes. The electrophoretic mobility of PGK, its Km for 3-phosphoglycerate and ATP, and its thermostability were normal. A slight For
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decrease in RBC PGK activity was found in the patient's mother, whereas the patient's father displayed normal erythrocyte PGK activity. These data are compatible with Xlinked genetic transmission. At the present time, the proband has marked mental retardation with frequent seizures associated with hemolytic anemia.
Enzymatic Studies
As previously reported, erythrocyte PGK activities in the proband in family B were very low (3.
The erythrocyte PGK activity in family V indicated a marked defect in enzyme activity in the proband (2.2 U/g Hb; normal 142 ? 33 U/g Hb). His father displayed a normal value (147 U/g Hb), as did his brother (123 U/g Hb) and sister (122 U/g Hb), whereas an intermediate value (96 Ulg Hb) was found in his mother.
Amplijcation Results
Amplification of the PGK gene was performed in seven parts according to the strategy described in Fig 1 and using the primers indicated in Table 1 . Preliminary studies in normal subjects indicated that a single product was obtained in regions covering the coding regions and flanking sequences. This result indicated that none of the primers, which were designed in intron sequences, hybridize with the multiple PGK pseudo gene^.^^^^^^ In an experiment using primers located in exons 7 and 8, we observed two PCR products, one with the normal size (corresponding to exons 7 and 8 plus intron 7) and a second shorter product lacking intron 7 (data not shown), which probably originated from a pseudogene. The sequence of this band was consistent with this hypothesis.
The results indicate that patient B has a G "* A interchange at position 1022 in cDNA (exon 9), which corresponds to the amino acid substitution 314 Asp -+ Asn (Fig 2a) . In the case of family V (Fig 2b) , the propositus was shown to have an A "* T interchange at position 571 in cDNA (exon S ) , which is responsible for the amino acid substitution 163 Asp + Val. His brother and his sister were normal, whereas the mother exhibited the same abnormality in the heterozygous state (ie, both a normal and abnormal bases were found in the same position). No other difference was observed, with the exception of position -27 upstream to the cap site of mRNA in the promoter region, where a T nucleotide was found in the place of a C for patient B; by contrast, members of family V, as well as the nine normal control DNAs (six of which were females), did not display this substitution, which could be classified as a sporadic mutation for patient B.
DISCUSSION
The technique followed in this report was derived from that used in our laboratory for another gene, bisphosphoglycerate mutase." Its use obviates subcloning of PCR products, which would have detected an error introduced by Taq polymerase, such an error being interpreted subsequently as a mutation during the sequencing step. In the case of PGK, which is an X-linked gene, a point mutation appears as an interchange for male patients, because there is only one allele present and it appears as the combination of the normal base with an abnormal base in the heterozygous state for females.
In the case of PGK CrCteil (nucleotide 1022 G + A in cDNA, 314 Asp + Am), and in addition to the enzymatic deficiency, the accompanying disorders mainly concerned rhabdomyolysis with acute renal failure, but no neurologic defect was observed. This case was extensively described previously by Rosa et al. 25 A deficient enzyme that possesses a mutation at the adjacent residue in PGK Michigan (nucleotide 1025 T + C in cDNA, 3 15 Cys "* Arg) has been described." This latter mutant is associated with hemolytic anemia and mental retardation, which is the more common pattern in PGK deficiency, but not with muscular disorders. Both the 314 and 315 residues belong to the C-terminal domain in the nucleotide binding site.* In these cases, the mechanism of PGK deficiency is easily understood if one considers the tertiary disruptions introduced by larger residues associated with the appearance of the new positive charge introduced by the arginine residue in PGK Michigan and by the replacement of aspartic acid, a negatively charged residue, by asparagine, a neutral residue, in PGK Crkteil.
In the case of PGK Amiens (nucleotide 571 A -+ T in cDNA, 163 Asp -+Val), the mutation occurs in the N-domain in a position that is localized to the catalytic domain. This localization accounts for the defect in enzymatic activity, as the change of a neutral residue for a negatively charged residue in PGK Amiens disrupts the tertiary structure of the molecule. Another mutant was recently described in the vicinity of residue 163, ie, PGK Shizuoka (nucleotide 552 G + T in cDNA, 157 Gly + In this case, it was supposed that the occurrence of a large residue instead of a very small one disrupted the tertiary structure, thus impairing the functional properties. PGK Shizuoka is associated with hemolytic anemia like in PGK Amiens but, in contrast to our case, it is not associated with mental retardation.
Both 167 and 315 aspartic acid residues were found to be invariant in all PGK amino acid sequences described up to now for humans, eukaryotes, and proeukaryotes. This indicates their functional importance in the enzymatic mechanism and that mutations observed in PGKs CrCteil and Amiens should impair it.
The nucleotide substitution observed in the promoter region in patient B could be explained either as a sporadic mutation found only in this given family or as a rare polymorphism, because it was not found in all the individuals studied, including members of the V family. For reasons given above (ie, Taq errors that are not detected in our strategy), and because it was the only base found at this position in a male patient, it is not an artefact but rather a real polymorphism. As described in other studies, polymorphic nucleotide interchanges leading to neutral mutations occur more frequently in regions of the gene where the selective pressure is less stringent, such as introns or flanking regions, or in regions where there is no binding site for a regulatory protein.
As shown above, the mechanism of the enzymatic defect may be readily understood because the amino acid substitution involves modifications in the tertiary structure. On the other hand, the relationship of the molecular PGK defect to the clinical features remains conjectural. The PGK CrCteil and PGK Michigan mutations are located on adjacent residues, but the former is associated with a muscular defect only, whereas the latter is associated with hemolytic anemia and mental retardation. A parallel observation can be made on comparison of PGK Amiens and PGK Shizuoka, whose respective mutations are located six residues apart but are associated with distinct clinical features." However, with the exception of triosephosphate isomerase deficiency and G6PD deficiency,"." no muscle manifestations have been reported in association with inherited defects of RBC metabolism, indicating that these two symptoms, ie, muscle mani- The latter are the only two cases in which PGK enzyme deficiency is associated with muscular disorders. Other cases of PGK deficiency associated with myoglobinuria have been described by DiMauro's group,22.2' but until now, the molecular defects of these mutants are not described. The explanation provided by Rosa et alZ5 for PGK Crkteil was supported by the fact that the enzymatic defect in muscle was responsible for the decrease in muscle glycogen content, which is needed for exercise. In the case of violent or prolonged muscular effort, the energy stocked in glycogen is rapidly consumed and myolysis occurs. However, it is surprising that PGK deficiency is not generally associated with muscular problems, because the enzyme is ubiquitous and the level of PGK activity is decreased in muscle as well as in other tissues.
On the other hand, the relationship between PGK deficiency and neurologic disorders remains to be established. Mental retardation is often associated with PGK deficiency. It is tempting to imagine that the chronic deficit of ATP induced by the decrease in glycolysis is responsible for the destruction of nervous cells to some degree, although such a mechanism seems to be more complex. Nevertheless, it is known that some enzymatic defects which do not impair glucose metabolism can be associated with mental retardation.'2." Mechanistic explanations for the clinical defects observed in RBC glycolytic enzyme deficiencies are lacking. However, it is to be anticipated that the description of further cases of deficient patients in association with the determination of the molecular defect by application of molecular techniques will allow more precise correlation between the location of the defect in the enzyme molecule, the decrease in enzymatic activity and, possibly, the clinical pattern observed.
